Sevelamer Crystals Linked to Dialysis Patient Colitis
A medical case report identified medication-related crystals as the cause of severe gastrointestinal distress.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Would you stop taking a prescribed medication if you experienced new, concerning side effects?
On September 14, 2026, researchers reported a case involving a 56-year-old dialysis patient whose chronic abdominal pain and diarrhea were caused by sevelamer crystals. The patient, who had been taking the phosphate binder with meals, recovered after discontinuing the medication.
Why it matters
This case highlights a known but rare complication of phosphate binder therapy in patients managing high phosphorus levels due to end-stage kidney disease. It underscores the importance of monitoring for gastrointestinal side effects like ulceration and necrosis in patients prescribed these medications.
The patient took 800 mg of sevelamer four times daily for three months, leading to symptoms that persisted until the medication was stopped. Clinical improvement was observed within four days of treatment cessation.
The players
Oxford Medical Case Reports
This is a medical journal that publishes peer-reviewed case reports covering various clinical specialties.
Renvela
This is a brand name for the phosphate binder medication sevelamer carbonate used to control phosphorus levels in patients with chronic kidney disease.
The details
Doctors discovered the issue after a colonoscopy revealed diffuse patchy erythema and biopsies showed brownish, fish-scale crystals lodged in colon ulcers. The crystals were identified as sevelamer carbonate, which had caused localized irritation in the digestive tract.
Timeline
2013: Pathologists first described the specific features of sevelamer crystals in medical literature.
September 14, 2026: The case report detailing the patient's condition was published in Oxford Medical Case Reports.
The Big Picture
This case report serves as a documented clinical application of the safety protocols established by Renvela prescribing labels. It highlights the rare but serious potential for medication-induced intestinal injury as warned by the manufacturer.
Patients undergoing dialysis who experience persistent gastrointestinal issues should consult their healthcare provider to discuss potential medication side effects. Clinicians may consider alternative phosphate binders if crystalline deposition or related inflammation is suspected.
The takeaway
Healthcare providers should maintain awareness that common binders can occasionally cause structural damage in the digestive tract. Early identification and medication adjustment can lead to rapid symptom resolution for affected patients.
Further reading
For more information on management of complications in chronic health conditions, visit our Diabetes section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Would you stop taking a prescribed medication if you experienced new, concerning side effects?
